|Articles|June 26, 2011

Sulfonylurea monotherapy ups CVD risk vs. metformin in older diabetics

Older patients started on oral antidiabetic therapy with a sulfonylurea have significantly higher risk for cardiovascular disease (CVD) events than patients started on metformin.

Stay informed with the Medical Economics eNewsletter, delivering expert insights, financial strategies, practice management tips, and technology trends tailored for today’s physicians.

Latest CME

Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Medical Economics

Physicians finally got a Medicare raise. Keeping it is the hard part.

AMA to corporate overlords: Doctors, not investors, must run physician practices

The $100,000 H-1B fee: Impact on the health care sector, legal challenge and current status

ADA ousts researchers then apologizes; Medicare Advantage reverses 95% of appealed denials; AMA takes on AI and corporate medicine — Morning Medical Update Weekly Recap